Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.

Virchows Archiv : an international journal of pathology - 1 Apr 2022

Ukkola Iiris, Nummela Pirjo, Kero Mia, Tammio Hanna, Tuominen Jenni, Kairisto Veli, Kallajoki Markku, Haglund Caj, Peltomäki Päivi, Kytölä Soili, Ristimäki Ari

Abstract excerpt

Gene fusions can act as oncogenic drivers and offer targets for cancer therapy. Since fusions are rare in colorectal cancer (CRC), their universal screening seems impractical. Our aim was to investigate gene fusions in 62 CRC cases with deficient MLH1 (dMLH1) and BRAFV600E wild-type (wt) status from a consecutive real-life series of 2079 CRCs. First, gene fusions were analysed using a novel FusionPlex Lung v2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Gene Fusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Immunohistochemistry

Share to Mutation

Share to MutL Protein Homolog 1

Share to Receptor, trkA

Source

Open in PubMed Open full text

Identifiers

PMID: 35237889
DOI: 10.1007/s00428-022-03302-x
PMCID: PMC9023403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.PMID 35237889Read ↗

Targeted next generation sequencing of MLH1 ‐deficient, MLH1 promoter hypermethylated, and BRAF / RAS ‐wild‐type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusionsSemantic proximity Read ↗

Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.Semantic proximity Read ↗

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsSemantic proximity Read ↗

MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.Semantic proximity Read ↗

Comprehensive Analysis of Oncogenic Fusions in Mismatch Repair Deficient Colorectal Carcinomas by Sequential DNA and RNA Next Generation SequencingSemantic proximity Read ↗

Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic CancersSemantic proximity Read ↗

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsSemantic proximity Read ↗

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.Semantic proximity Read ↗

Genomic landscape and therapeutic implications of Anaplastic Lymphoma Kinase fusion-positive colorectal cancer.Semantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Detection of NRG1 Gene Fusions in Solid TumorsSemantic proximity Read ↗

Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.